L Ashcroft
Overview
Explore the profile of L Ashcroft including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
225
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tay R, Fernandez-Gutierrez F, Foy V, Burns K, Pierce J, Morris K, et al.
Ann Oncol
. 2019 Apr;
30(7):1114-1120.
PMID: 31020334
Background: The clinical significance of circulating tumour cells (CTCs) in limited-stage small-cell lung cancer (LS-SCLC) is not well defined. We report a planned exploratory analysis of the prevalence and prognostic...
2.
Khoja L, Nolan K, Mekki R, Milani A, Mescallado N, Ashcroft L, et al.
Clin Oncol (R Coll Radiol)
. 2016 Jul;
28(12):760-765.
PMID: 27401967
Aims: Ovarian cancer is the principal cause of gynaecological cancer death in developed countries, yet overall survival in the UK has been reported as being inferior to that in some...
3.
Bayman N, Ardron D, Ashcroft L, Baldwin D, Booton R, Darlison L, et al.
BMJ Open
. 2016 Jan;
6(1):e010589.
PMID: 26817643
Introduction: Histological diagnosis of malignant mesothelioma requires an invasive procedure such as CT-guided needle biopsy, thoracoscopy, video-assisted thorascopic surgery (VATs) or thoracotomy. These invasive procedures encourage tumour cell seeding at...
4.
Challberg J, Ashcroft L, Lalloo F, Eckersley B, Clayton R, Hopwood P, et al.
Br J Cancer
. 2011 Jun;
105(1):22-7.
PMID: 21654687
Background: Women at high ovarian cancer risk, especially those with mutations in BRCA1/BRCA2, are encouraged to undergo bilateral risk-reducing salpingo-oophorectomy (BRRSPO) prior to the natural menopause. The decision to use...
5.
Wheatley-Price P, Blackhall F, Lee S, Ma C, Ashcroft L, Jitlal M, et al.
Ann Oncol
. 2010 Mar;
21(10):2023-2028.
PMID: 20332134
Background: Some non-small-cell lung cancer (NSCLC) surgical series have indicated that the positive prognostic effect of female sex is limited to patients with adenocarcinoma. We carried out a retrospective analysis...
6.
Maurice A, Evans D, Shenton A, Ashcroft L, Baildam A, Barr L, et al.
Eur J Cancer
. 2006 Jun;
42(10):1385-90.
PMID: 16750910
Women with a family history are often offered mammographic surveillance at an earlier age and with greater frequency than those in the National Breast Screening Programme. In this study, we...
7.
Booton R, Lorigan P, Anderson H, Baka S, Ashcroft L, Nicolson M, et al.
Ann Oncol
. 2006 Apr;
17(7):1111-9.
PMID: 16603599
Background: Phase III studies suggest that non-small-cell lung cancer (NSCLC) patients treated with cisplatin-docetaxel may have higher response rates and better survival compared with other platinum-based regimens. We report the...
8.
Baka S, Ashcroft L, Anderson H, Lind M, Burt P, Stout R, et al.
J Clin Oncol
. 2005 Feb;
23(10):2136-44.
PMID: 15713598
Purpose: This randomized phase II study compared two treatment schedules of gemcitabine in patients with non-small-cell lung cancer (NSCLC) and impaired Karnofsky performance status (KP). Primary objectives were to record...
9.
Danson S, Lorigan P, Arance A, Clamp A, Ranson M, Hodgetts J, et al.
J Clin Oncol
. 2003 Jun;
21(13):2551-7.
PMID: 12829675
Purpose: Temozolomide is an imidazotetrazine with a mechanism of action similar to dacarbazine and equivalent activity in melanoma. It is well tolerated and is a candidate for combination chemotherapy and...
10.
Burgers J, Arance A, Ashcroft L, Hodgetts J, Lomax L, Thatcher N
Br J Cancer
. 2002 Aug;
87(5):562-6.
PMID: 12189557
Patients who are treated within clinical trials may have a survival benefit dependent on being a trial participant. A number of factors may produce such beneficial outcome including more rigorous...